Murchinson Criticizes the Nano Dimension Board of Directors’ Decision to Pursue a Seemingly Deeply Flawed Transaction with Infinite Epigenetics
Believes the Proposed Transaction Represents a Misallocation of Corporate Resources That Would Significantly Dilute Existing Shareholders Finds It Deeply Concerning That This Morning’s Conference Call Offered Shareholders Little Beyond Buzzwords and Provided No Opportunity to Ask
TORONTO -- Murchinson Ltd. (collectively with its affiliates and funds it advises and/or sub-advises, "Murchinson" or "we"), a significant shareholder with approximately 7.4% of the outstanding shares of Nano Dimension Ltd. (NASDAQ: NNDM) ("Nano" or the "Company"), today commented on Nano’s announcement that it has signed a non-binding term sheet with Infinite Epigenetics (“Infinite” or “Infinite Epigenetics”) to form a publicly traded, AI-powered health and diagnostics company.1 Read More
Đọc thêm từ Tài chính
CNBC's The China Connection newsletter: Waiting for AI to lift the whole market
China's economy sees a lift from artificial intelligence-related industries, while real estate and domestic demand remain lackluster.